Sekundäre Osteoporose – praxisrelevante Besonderheiten bei der Diagnostik und Therapie

Zusammenfassung

Osteoporose ist eine systemische Skeletterkrankung mit erhöhtem Frakturrisiko. Nach den Ursachen wird zwischen primären (70 – 80 %) und sekundären (20 – 30 %) Osteoporosen unterschieden. Sekundäre Osteoporosen sind alle Formen, die überwiegend und kausal mit bestimmten Erkrankungen und Konditionen verknüpft sind. Ziel der Arbeit ist es, Besonderheiten bei der Diagnosestellung, Prophylaxe und Therapie von sekundären Osteoporosen im Allgemeinen und anhand einiger für die Praxis besonders bedeutsamer Formen darzustellen. Dabei wird auf die Leitlinien des Dachverbandes Osteologie (DVO) von 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose und zu ausgewählten Originalarbeiten zu einzelnen Osteoporoseformen Bezug genommen. Richtungsweisend für die Diagnose sind Anamnese, klinische Untersuchung und Basis-Labordiagnostik. Die sekundären Osteoporosen sind oft durch eine rasche Entstehung und schwere Verlaufsformen gekennzeichnet. Entscheidend sind eine frühzeitige Diagnostik, eine Prophylaxe und – wenn möglich – eine rasche kausale Therapie bzw. eine knochenspezifische Therapie, da bereits bei geringerer Erniedrigung der Knochendichte das Frakturrisiko steigt. Die wichtigsten Ursachen einer sekundären Osteoporose sind Medikamente sowie endokrine, gastrointestinale und hämatologische Erkrankungen. Exemplarisch werden die Glukokortikoid-induzierte Osteoporose, die antihormonelle Therapie (Aromatase-Inhibitoren bei Frauen mit Mammakarzinom und antiandrogene Therapie bei Männern mit Prostatakarzinom) sowie ein Vitamin-D-Mangel mit sekundärem Hyperparathyreoidismus dargestellt. Anamnese und Basislabor sind entscheidend, um mögliche Ursachen für eine sekundäre Osteoporose rechtzeitig zu erkennen und eine frühzeitige Diagnostik durchzuführen. Durch eine rasche kausale Therapie oder eine risikoadaptierte medikamentöse Osteoporose-Therapie lässt sich das Risiko für die Entstehung schwerer Osteoporosen mit multiplen Frakturen verringern.

Abstract

Osteoporosis is a systemic skeletal disease causing increased fracture risk. According to pathogenesis, primary (70 – 80 %) and secondary osteoporosis (20 – 30 %) are distinguished. Secondary osteoporosis comprises all entities in which osteoporosis is predominantly and causally associated with certain diseases or conditions. The aim of this review article is to put attention to special features in diagnosis, prophylaxis and treatment of secondary osteoporosis in general and to demonstrate some forms of secondary osteoporosis which seem particularly important during clinical practice. The manuscript refers to the guidelines of the DVO 2009 for prevention, diagnosis and therapy of osteoporosis and selective original papers considering the special types of secondary osteoporosis. History, clinical examination and basic laboratory tests are indicative for the diagnosis of secondary osteoporosis. Its clinical presentation is frequently characterized by rapid development and multiple fractures. Therefore, early diagnosis, prophylaxis and causal treatment is decisive. If causal treatment is impossible, risk adaption of bone mineral density (BMD) for osteoporosis specific treatment is essential. Common causes are medications, endocrine, gastrointestinal and hematologic diseases. Glucocorticoid induced osteoporosis, antihormonal therapy (aromatase inhibitor in women with breast cancer, androgen deprivation therapy in men with prostate cancer) and vitamin D deficiency causing secondary hyperparathyroidism are presented in detail. History and basic laboratory testing are decisive to identify possible causes for secondary osteoporosis and to initiate early diagnostic procedures. The risk of severe osteoporosis can be reduced by early and causal treatment or by risk stratified early bone specific medication if causal therapy is impossible.

Schlüsselwörter

Osteoporose - Frakturen - Knochendichte - Glukokortikoide - Vitamin D - Aromatase-Inhibitoren - Hyperparathyreoidismus

Keywords

osteoporosis - fractures - bone mineral density - glucocorticoids - vitamin D - aromatase inhibitors - hyperparathyroidism

• Literatur

• 1 Ambrogini E, Cetani F, Cianferotti L et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007; 92: 3114-3121
• 2 Bartl C, Bartl R. Sekundäre Osteoporose: Pathogenese, Formen, Diagnostik und Therapie. Radiologe 2011; 51: 307-324
• 3 Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009; 339: b3692
• 4 Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25: 829-836
• 5 Bundred NJ, Campbell ID, Davidson N et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008; 112: 1001-1010
• 6 Caplan GA, Scane AC, Francis RM. Pathogenesis of vertebral crush fractures in women. J R Soc Med 1994; 87: 200-202
• 7 Cauley JA, Lacroix AZ, Wu L et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008; 149: 242-250
• 8 Cerda Gabaroi D, Peris P, Monegal A et al. Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause 2010; 17: 135-139
• 9 Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42: 2309-2318
• 10 Corley DA, Kubo A, Zhao W et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139: 93-101
• 11 Crawford BA, Liu PY, Kean MT et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88: 3167-3176
• 12 Diamond TH, Winters J, Smith A et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001; 92: 1444-1450
• 13 DVO. DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose 2009. www.dv-osteologie.de
• 14 Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008; 26: 1051-1057
• 15 Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875-4882
• 16 Gallagher JC, Sai AJ. Bone: Is screening for secondary causes of osteoporosis worthwhile?. Nat Rev Endocrinol 2010; 6: 360-362
• 17 Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691
• 18 Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Intern Med 2010; 170: 765-771
• 19 Greenspan SL, Brufsky A, Lembersky BC et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008; 26: 2644-2652
• 20 Hermus AR, Smals AG, Swinkels LM et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995; 80: 2859-2865
• 21 Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-4057
• 22 Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
• 23 Israeli RS, Rosenberg SJ, Saltzstein DR et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007; 5: 271-277
• 24 Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893-899
• 25 Kiratli BJ, Srinivas S, Perkash I et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127-132
• 26 Kumar J, Muntner P, Kaskel FJ et al. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics 2009; 124: e362-370
• 27 Leidig-Bruckner G, Hosch S, Dodidou P et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001; 357: 342-347
• 28 Leidig-Bruckner G, Roth HJ, Bruckner T et al. Are commonly recommended dosages for vitamin D supplementation too low? Vitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels-an observational study during clinical practice conditions. Osteoporos Int 2010; 22: 231-240
• 29 Mauri D, Valachis A, Polyzos NP et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw 2010; 8: 279-286
• 30 Pfeilschifter J. Risikostratifizierte Therapie der Osteoporose. Dtsch Med Wochenschr 2011; 136: 525-532
• 31 Rao DS, Phillips ER, Divine GW et al. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004; 89: 5415-5422
• 32 Reid DM, Devogelaer JP, Saag K et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253-1263
• 33 Reid DM, Doughty J, Eastell R et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 (01) 3-18
• 34 Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006-1013
• 35 Reid IR, Wattie DJ, Evans MC et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173-1177
• 36 Saad F, Adachi JD, Brown JP et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008; 26: 5465-5476
• 37 Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. y Group. N Engl J Med 1998; 339: 292-299
• 38 Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-2039
• 39 Scane AC, Francis RM. Risk factors for osteoporosis in men. Clin Endocrinol (Oxf) 1993; 38: 15-16
• 40 Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164
• 41 Silverberg SJ, Shane E, Jacobs TP et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341: 1249-1255
• 42 Smith MR, Eastham J, Gleason DM et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012
• 43 Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755
• 44 Smith MR, Lee WC, Brandman J et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903
• 45 Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955
• 46 Tannenbaum C, Clark J, Schwartzman K et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002; 87: 4431-4437
• 47 Valachis A, Polyzos NP, Georgoulias V et al. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. Gynecol Oncol 2010; 117: 139-145
• 48 Van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000
• 49 Vestergaard P, Mollerup CL, Frokjaer VG et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000; 321: 598-602
• 50 Yang YX, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953